GlassScriptPhysician profile
Laverne Dowell
NPI 1306222419
$8,770.22
in general payments reported to CMS, 2019-2025
26 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,457 · 2022: $1,249 · 2023: $2,683 · 2024: $1,492 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,800 · Travel and Lodging: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,799.96 |
| Travel and Lodging | $263.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,640.31 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,336.84 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,291.75 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $1,101.69 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $576.17 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $450.97 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neuronetics, INC. | $388.43 | 2025 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $299.18 | 2021-2023 | Trintellix |
| Lundbeck LLC | $249.29 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.03 | 2021-2025 | Caplyta |
| Viiv Healthcare Company | $210.03 | 2022-2023 | Cabenuva |
| Axsome Therapeutics, INC. | $202.80 | 2022-2025 | Auvelity |
| Indivior INC. | $181.70 | 2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $122.40 | 2024 | Quviviq |
| Neurocrine Biosciences, INC. | $104.20 | 2024-2025 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $95.63 | 2023 | Biktarvy |
| Avanir Pharmaceuticals, INC. | $68.84 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $65.10 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $39.64 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $28.31 | 2021 | |
| Lilly USA, LLC | $19.27 | 2023 | Mounjaro |
| Mannkind Corporation | $17.21 | 2021 | |
| Novo Nordisk INC | $15.76 | 2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $15.46 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.32 | 2025 | Gvoke Hypopen |
| Bausch Health US, LLC | $13.89 | 2025 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laverne Dowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.